Centessa Pharmaceuticals (CNTA) investor relations material

Leadership vision and strategic direction

• CEO emphasizes a defining moment for neurosciences, focusing on rare hypersomnias and a best-in-class orexin-2 agonist program.

• The company aims to provide a functional cure for NT1 and a paradigm shift in treatment for rare hypersomnia patients.

• Vision includes developing assets with diverse PK profiles to address broader neuroscience indications.

• Transitioning from a rare hypersomnia-focused entity to a broader neurosciences company with a pipeline approach.

• Building a commercial team and preparing for pre-commercial stage operations.

Clinical development and data updates

• Early phase 2 data showed normalization of ESS and significant cataplexy reduction at low doses in NT1, NT2, and IH.

• Achieved clinically meaningful efficacy across all three rare hypersomnias, with plans to escalate doses for extended duration.

• Phase 2 study design allows for adaptive dose selection and ongoing optimization.

• Upcoming Q1 update may include new data and initiation of registration studies in one or more indications.

• Open-label extension is ongoing, with efficacy being monitored over several weeks.

Differentiation and best-in-class aspirations

• Best-in-class defined holistically by efficacy, safety, tolerability, and especially duration of action.

• Drug designed for a wide therapeutic index, enabling higher dosing and flexible regimens.

• Split dosing and titration are being evaluated to enhance patient flexibility and tolerability.

• No significant dose-response in polyuria observed; titration may further reduce adverse events.

• No evidence of tachyphylaxis or receptor internalization in preclinical or clinical studies.